Skip to main content
OpenTrials

Clinical trial condition

Fallopian Tube Diseases

Explore clinical trials studying Fallopian Tube Diseases. Study availability and eligibility vary by location and protocol.

598 public trials 89 recruiting studies
Refine in advanced search Browse all conditions

Fallopian Tube Diseases trial results

Active, Not Recruiting

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02101775

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +33 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Decatur Memorial Hospital Decatur, Illinois, United States
View all 16 locations
View Trial Details
Active, Not Recruiting

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

NCT05446298

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +18 more
Locations
  • Cancer Treatment Centers of America, Phoenix. 403 Goodyear, Arizona, United States
  • Honor Health, USOR, 406 Phoenix, Arizona, United States
  • Nuvance Health System, 401 Danbury, Connecticut, United States
  • Baptist MD Anderson Cancer Center, 404 Jacksonville, Florida, United States
View all 21 locations
View Trial Details
Active, Not Recruiting

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

NCT05858736

Conditions
Adenocarcinoma, Adnexal Diseases, Anal Cancer, +85 more
Locations
  • St. Vincent's Private Hospital Darlinghurst, New South Wales, Australia
  • Mater Misericordiae Ltd. Brisbane, Queensland, Australia
  • Tasman Oncology Research Southport, Queensland, Australia
  • Cancer Research SA Adelaide, South Australia, Australia
View Trial Details
Active, Not Recruiting

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

NCT05335993

Conditions
Adenocarcinoma of Ovary, Adnexal Diseases, Carcinoma, +25 more
Locations
  • Duke Cancer Center Durham, North Carolina, United States
  • Stephenson Cancer Center- University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma, United States
  • University of Virginia Health System Charlottesville, Virginia, United States
View Trial Details
Active, Not Recruiting

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

NCT05605535

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +18 more
Locations
  • Omega Hospitals Visakhapatnam, Andhra Pradesh, India
  • King George Hospital Visakhapatnam, Andhra Pradesh, India
  • Himalaya Cancer Hospital and Research Institute Vadodara, Gujarat, India
  • Kailash Cancer Hospital and Research Centre Vadodara, Gujarat, India
View all 14 locations
View Trial Details
Active, Not Recruiting

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

NCT04498117

Conditions
Abdominal Neoplasms, Adnexal Diseases, Carcinoma, +29 more
Locations
  • Honor Health Phoenix, Arizona, United States
  • The University of Arizona Cancer Center Tucson, Arizona, United States
  • John Muir Health Clinical Research Center Concord, California, United States
  • Kaiser Permanente Southern California Irvine, California, United States
View all 148 locations
View Trial Details
Active, Not Recruiting

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

NCT02873962

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
View Trial Details

Related conditions